Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 33087
Induction of Apoptosis by Newcastle Disease Virus Strains AF220 and V4-UPM in Human Promyelocytic Leukemia (HL60) and Human T-Lymphoblastic Leukemia (CEM-SS) Cells
Authors: Siti Aishah Abu Bakar, Madihah Zawawi, Abdul Manaf Ali, Aini Ideris
Abstract:
Newcastle Disease Virus (NDV), an avian paramyxovirus, is a highly contagious, generalised virus disease of domestic poultry and wild birds characterized by gastro-intestinal, respiratory and nervous signs. In this study, it was shown that NDV strain AF2240 and V4-UPM are cytolytic to Human Promyelocytic Leukemia, HL60 and Human T-lymphoblastic Leukemia, CEM-SS cells. Results from MTT cytolytic assay showed that CD50 for NDV AF2240 against HL60 was 130 HAU and NDV V4-UPM against HL60 and CEM-SS were 110.6 and 150.9 HAU respectively. Besides, both strains were found to inhibit the proliferation of cells in a dose dependent manner. The mode of cell death either by apoptosis or necrosis was further analyzed using acridine orange and propidium iodide (AO/PI) staining. Our results showed that both NDV strains induced primarily apoptosis in treated cells at CD50 concentration. In conclusion, both NDV strains caused cytolytic effects primarily via apoptosis in leukemia cells.Keywords: Apoptosis, Cytolytic, Leukaemia, Newcastle DiseaseVirus
Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1332156
Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1973References:
[1] K. W. Reichard, R. M. Lorence, C. J. Cascino, M. E. Peeples, R. J. Walter, M. B. Fernando, H. M. Reyes and J. A. Greager. "Newcastle disease virus selectively kills human tumor cells," J. Surg. Res., 1992, 52: 448-453.
[2] A. R. Omar, A. Ideris, A. M. Ali, F. Othman, K. Yusoff, J. M. Abdullah et al. "An overview of the development of Newcastle disease virus as an anti-cancer therapy," Malaysian J Med Sci., 2002, 9: 4-12.
[3] D. J. Alexander, "Newcastle disease and other avian Paramyxoviridae infections," in Diseases of Poultry, 10th ed., B. W. Calneck, Ed. Ames, IA: Iowa State University Press, 1997, pp. 541-569.
[4] M. A. Mayo. 2002. "A summary of taxonomic changes recently approved by ICTV". Arch. Virol., 2002, 147: 1655-1666.
[5] D. J. Alexander, "Newcastle disease," in A Laboratory Manual for the Isolation and Identification of Avian Pathogens, 3rd ed., H. G. Purchase, L. H. Arp, C. H. Domermuth and J. E.Pearson, Eds. Kennett Square, PA: American Association of Avian Pathologists, 1989, pp. 114-120.
[6] F. M. Batliwalla, B. A. Bateman, D. Serrano, D. Murray, S. Macphail, V. C. Maino et al. "15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell Noun 1. CD8 T cell - T cell with CD8 receptor that recognizes antigens on the surface of a virus-infected cell and binds to the infected cell and kill itCD8 cell, cytotoxic T cell, killer cell, killer T cell repertoire," Mol Med., 1998, 4: 783-794.
[7] V. Schirrmacher, A. Griesbach and T. Ahlert. "Anti-tumour effects of Newcastle Disease Virus in vivo: local versus systemic effects," Int J Oncol., 2001, 18 : 945-52.
[8] R. M. Lorence, A. L. Pecora, P. P. Major, S. J. Hotte, S. A. Laurie, M. S. Roberts et al. 2003. "Overview of phase I studies of intravenous administration of PV701, an oncolytic virus," Curr Opin Mol Ther., 2003, 5: 618-624.
[9] P. B. Spradbrow and J. L. Samue, "Oral Newcastle disease vaccine in experimental chickens in Australia," in Newcastle Disease in poultry, J. W. Copland, Ed. ACIAR: Canberra, 1987, pp: 44-49. 1987.
[10] H. Westbury. "Newcastle disease virus: an evolving pathogen," Avian Pathology, 2001, 30: 5-11.
[11] M. C. Lai and A. L. Ibrahim, "Velogenic-viscerotropic Newcastle disease virus," in New castle disease virus in poultry, J.W. Copland Ed. ACIAR Monograph.1987.
[12] W. S. Tan, C. H. Lau, B. K. Ng, A. L. Ibrahim and K. Yusoff. "Nucleotide sequence of the haemagglutinin-neuraminidase (HN) gene of a Malaysian heat resistant viscerotropic-velogenic Newcastle disease virus," DNA Sequence, 1995, 6: 47-50.
[13] K. Yusoff and W. S. Tan. "Newcastle disease virus: macromolecules and opportunities," Avian Pathology, 2001, 30: 439-455.
[14] M. Meyyappan. "Oncolytic effect of Newcastle disease virus on the MCF-7 and MDA-231 breast cancer cell lines," Master Thesis, Universiti Putra Malaysia, Malaysia, 2003.
[15] H. S. M. Wali. "The effects of Newcastle Disease Virus (NDV) on breast cancer cell lines," Master Thesis, Universiti Putra Malaysia, Malaysia, 2003.
[16] M. Aied. "Antileukaemic effect of local Newcastle disease virus strains AF2240 and V4-UPM on leukaemia cell lines in vitro and in vivo," Ph. D Thesis. Universiti Putra Malaysia, Malaysia, 2007.
[17] Rola Ali, Aied M. Alabsi, Abdul Manaf Ali, Aini Ideris , Abdul Rahman Omar and Khatijah Yousoff. "Apoptosis Induction and Cytolytic Effects of Newcastle Disease Virus Strain Af2240 on DBTRG.05 mg Brain Tumor Cell Line." International Journal of Cancer Research, 2011, 7: 25-35.
[18] D. J. Alexander, "Newcastle Disease Diagnosis," in Newcastle Disease, D. J. Alexander, Ed. Kluwer Academic Publishers: Norwell, Massachusetts, 1988, pp: 147-160.
[19] P. Chambers and A. C. R. Samson. "A new structural protein for newcastle disease virus," J. General Virol.1980, 50: 155-166.
[20] K. Yusoff, W. S. Tan, C. H. Lau, B. K. Ng and A. L. Ibrahim. "Sequence of the haemagglutinin-neuraminadase gene of the Newcastle disease virus oral vaccine strain V4 (UPM)," Avian Pathol., 1996, 25: 837-844.
[21] R. M. Lorence, P. A. Rood and K. W. Kelley. "Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity," J Natl Cancer Inst., 1988, 80: 1305- 1312.
[22] U. Zorn, I. Dallmann, J. Grosse J. et al. "Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus," Cancer Biother., 1994, 9: 225-235.
[23] Y. Tzadok-David, M. Metzkin-Eizenberg, Z. Zakay-Rones. "The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells," J Cancer Res Clin Oncol., 1995, 121: 169-174.
[24] T. Ahlert and V. Schirrmacher. "Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns," Cancer Res., 1990, 50: 5962-5968.
[25] P. V Ravindra, A. K. Tiwari, B. Ratta, U. Chaturvedi, S. K. Palia, P. K. Subudhi et al. "Induction of apoptosis in Vero cells by Newcastle disease virus requires viral replication, de-novo protein synthesis and caspase activation," Virus Res., 2008, 133: 285-290.
[26] B. Washburn, M. A. Weigand, A. Grosse-Wilde, M. Janke, H. Stahl, E. Rieser, M. R. Sprick, V. Schirrmacher and H. Walczak. "TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus," J. Immunol., 2003, 170: 1814-1821.
[27] J. F. R. Kerr, A. H. Wyllie and A. R. Currie. "Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics," Br. J. Cance., 1972, 26: 239-257.
[28] A. H. Wyllie, J. F. R. Kerr and A. R. Currie. "Cell death: the significance of apoptosis," Int. Rev. Cytol., 1980, 68: 251-306.
[29] S. A. Jahanmehr, K. Hyde, C. G. Geary et al. "Simple technique for fluorescence staining of blood cells with acridine orange," J Clin Pathol., 1987, 40: 926-929.
[30] A. J. McGohan, S. J. Martin, R. P. Bissonette, A. Mahboubi, Y. Shi, R. J. Mogil, W. K. Nishioka and D. R. Green, in Methods in Cell Biology, L.M Schwartz and B.A Osborne, Eds. London: Academic Press Incorporated. 1995, pp. 153-185.
[31] K. Mascotti, J. McCullough and S. R. Burger. "HPC viability measurement: Trypan blue versus acridine orange and propidium iodide," Transfusion, 2000, 40: 693-696.